1. Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: stage 1 results from the TELLOMAK phase 2 trial. (September 2022) Authors: Bagot, M; Muller, M; Kim, YH; Ortiz-Romero, PL; Zinzani, PL; Beylot-Barry, M; Dalle, S; Jacobsen, E; Combalia, A; Huen, A; Mehta-Shah, N; Khodadoust, MS; Viotti, J; Paiva, C; Porcu, P Journal: European journal of cancer Issue: Volume 173(2022)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗